Surgery and drug therapy for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older
- You have stomach or gastroesophageal junction cancer that has not spread far but cannot be surgically removed yet
- Your cancer is HER2 positive (cohorts A and B) or CLDN18.2 positive (cohorts C and D)
- You are in good enough health to have surgery and receive study drugs
- You are able to have a pregnancy test and use effective birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs, trastuzumab deruxtecan and afatinib, together for advanced stomach or gastroesophageal junction cancer that has low levels of the HER2 protein. The goal is to see if the combination shrinks tumors or slows cancer growth.
This trial tests a new drug called zolbetuximab combined with chemotherapy (docetaxel, oxaliplatin, S-1) before surgery for people with locally advanced stomach cancer that has a specific protein (CLDN18.2). The goal is to see if this combination shrinks tumors enough to improve surgery outcomes.
This trial tests a combination of anti-cancer medicines for HER2-positive advanced stomach cancer that has already been treated once. It may help shrink tumors and slow the disease by targeting HER2 and blocking tumor blood supply.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
This trial tests a combination of two targeted drugs, with or without chemotherapy, given before and after surgery for stomach or gastroesophageal junction cancer. It aims to improve the chance of curing the cancer by shrinking it before surgery and controlling any remaining cancer after surgery.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
Hear when a new Stomach Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.